

# UBAM - SWISS EQUITY

## Quarterly Comment

For Professional Investors in Switzerland or Professional Investors as defined by the relevant laws

### Market Comment

- In Q3, all major equity markets posted positive returns, though with a downturn in September for most of them. The MSCI AC World finished up +8.1%. At regional level, Emerging equities were up +9.6%, US equities +8.9%, Japanese equities +5.2%, and European Equities +0.1%. As for Swiss equities, the SPI was up +2.3% and the SPI Extra ended Q3 2020 at +6.4%. YTD, the SPI and the SPI Extra have returned -0.9% and -0.7% respectively, whereas the MSCI AC World was up +1.4%.
- Economic activity continued its reopening recovery, but with fading momentum at the end of the quarter, pointing towards a still positive but slower growth pace in Q4. In the US, the manufacturing sector is in good shape with the PMI at 53.5, but in September the services sector activity declined for the first time since April from 55 to 54.6. The same happened in Europe with an increased divergence between a good momentum in the manufacturing sector and a negative sentiment in the services sector, impacted by renewed social distancing measures and constraints on hospitality.
- At the end of the quarter, the US continued to show positive earnings momentum across all sectors, whereas the picture was more mixed elsewhere. Furthermore, except for Materials, regional disparities across sectors were significant. Among the major markets, expected earnings growth rates for 2020 range from +0% for China to -39% for both the UK and eurozone, with the US roughly in the middle of the range (-16%). A sharp earnings rebound is anticipated in all major regions next year, notably for the eurozone (+55%). Regarding the major valuation metrics for global equities, the 12m forward PE fell to 19x after having exceeded 20x during the summer, the price-to-book ratio remained at 113% of its 5-year average while the 12m fwd ROE increased slightly to 90% of its longer term average.
- Switzerland's KOF indicator continued its rebound in September from 110.2 to 113.8 and now exceeds the highs seen in 2017. Unemployment continued to increase slightly over the month, but the unemployment rate remained stable. The Swiss GDP is now expected to contract by 5% this year, a drop smaller than that expected in other countries.
- Over the third quarter of 2020, most sectors contributed positively to the SPI's performance with Consumer Staples, Industrials and Materials adding the most while Health Care and Financials detracted. In terms of single names, the best contributors were Nestlé, Sika and Lonza, while Roche, Novartis and UBS detracted the most.

---

## Performance Review

- Over Q3 2020, UBAM - Swiss Equity delivered +5.1% in gross performance versus +2.3% for the SPI. YTD, the fund accumulated +3% in gross excess return over the benchmark. Over Q3, most of the outperformance came from stock selection, contributing 2.6% to excess returns, while sector allocation contributed 0.2%. Stock selection in the Healthcare sector was particularly positive, with a contribution of 1.6%. The Materials sector also contributed very positively thanks to successful stock picking and its overweight in the portfolio given the strong performance over the quarter.
- In terms of individual names, the best relative contributors over the quarter were the overweights in Lonza and Sika (+51bps and +43bps respectively) and the underweight in Roche (+50bps). Lonza continued to enjoy positive momentum over the month of July as several analysts upgraded their numbers after the strong H1 results. The stock stayed flat over August and September but still ended the quarter up 14%. Sika had an exceptional quarter with the stock price up more than 24%. The company posted good H1 results and confirmed its 2023 targets ahead of a well-received capital markets day at the end of the quarter. Roche had a bit of a rollercoaster quarter ending it down -4%. The stock first sold off after underwhelming H1 results towards the end of July but then recovered nicely until mid-September when one of their pipeline drugs missed an endpoint in a phase 2 trial for Alzheimer's disease and sales of its multiple sclerosis drug Ocrevus declined in the US.
- The biggest relative detractors over the quarter were the forced underweight in Nestlé (-30bps), as well as the overweights in Zur Rose (-28bps) and Idorsia (-25bps). After Nestlé climbed back up to close to all-time highs in July it saw some profit taking despite delivering decent H1 results at the end of July. The stock did not move much for the remainder of the quarter and ended it up +4%. Zur Rose, whose share price nearly tripled from the beginning of the year to its peak in mid-July, sold off after H1 results in August revealed a bigger than expected loss due to continued investments. The stock ended the quarter down -15%. Idorsia's share price lost 18% over the quarter. It first suffered a significant drop due to a placement by its majority shareholder Johnson & Johnson in July. In early September the stock felt renewed pressure as some analysts voiced concerns that its main pipeline drug daridorexant's profile was not substantially differentiated from other currently available drugs challenging its commercial prospects in the US.

---

## Portfolio Activity

- Over the month of July, a new position was initiated in Comet – a previously held name – whose leadership in x-ray tubes and matchboxes for the semiconductor industry allowed it to navigate Covid-19 more or less unscathed posting a year-on-year increase in sales and profits for the first half of 2020.
- No major changes were done on the portfolio level over the month of August.
- In September, the team sold its position in Swisscom to finance a position in Sonova towards the end of the month as the company significantly increased its guidance due to a faster than expected market recovery, successful internal growth and productivity initiatives as well as the promising launch of the next generation of their connected hearing devices.

---

## Outlook

- As we head into the last quarter of the year, equity investors continue to face uncertainties around the Covid-19 pandemic and the outcome of the US elections. A re-election of Mr. Trump could increase pressure on global trade and the economy in a post-Covid recovery while deregulation and tax reductions could be a tailwind for equity markets. With a Biden win, the Trump corporate tax cut of 2017 could be at risk to be partially reversed, while we could see increased stimulus and spending on climate change mitigation as well as increased access to federally funded healthcare. A divided government could lead to gridlocks in tax and spending regulation and higher volatility would be expected for equity markets.
- The expected earnings decline this year (-10%) and recovery next year (+17%) are a lot more benign for Swiss equities than any other major equity market implying lower risk of downgrades to the 2021 estimates. In addition, the Swiss market usually trades at a premium to the MSCI AC World due to the superior value creation of Swiss companies. Currently, it only trades in line with global markets at 19x and at a significant discount to the US at close to 22x. Finally, while the Swiss market has significantly outperformed global markets during the peak of the Covid-crisis, it has slightly underperformed since lockdowns have started to ease. With potentially more volatility in the quarter ahead this could reverse providing yet another reason why this could be a good opportunity to build or increase an allocation to Swiss equities.

**This is a marketing document and is intended for informational and/or marketing purposes only. It is confidential and is intended to be used only by the person(s) to whom it was delivered.** It may not be reproduced (in whole or in part) or delivered, given, sent or in any other way made accessible, to any other person without the prior written approval of Union Bancaire Privée, UBP SA or any entity of the UBP Group (UBP). This document reflects the opinion of UBP as of the date of issue. This document is for distribution only to persons who are Professional clients in Switzerland or Professional Clients or an equivalent category of investor as defined by the relevant laws (all such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. It is not intended for distribution, publication, or use, in whole or in part, in any jurisdiction where such distribution, publication, or use would be unlawful, nor is it directed at any person or entity at which it would be unlawful to direct such a document. In particular, this document may not be distributed in the United States of America and/or to US persons (including US citizens residing outside the United States of America). This document has not been produced by UBP's financial analysts and is not to be considered financial research. It is not subject to any guidelines on financial research and independence of financial analysis. Reasonable efforts have been made to ensure that the content of this document is based on information and data obtained from reliable sources. However, UBP has not verified the information from third sources in this document and does not guarantee its accuracy or completeness. UBP makes no representations, provides no warranty and gives no undertaking, express or implied, regarding any of the information, projections or opinions contained herein, nor does it accept any liability whatsoever for any errors, omissions or misstatements. The information contained herein is subject to change without prior notice. UBP gives no undertaking to update this document or to correct any inaccuracies in it which may become apparent. This document may refer to the past performance of investment interests. **Past performance is not a guide to current or future results.** The value of investment interests can fall as well as rise. Any capital invested may be at risk and investors may not get back some or all of their original capital. Any performance data included in this document does not take into account fees, commissions, and expenses charged on issuance and redemption of securities, nor any taxes that may be levied. Changes in exchange rates may cause increases or decreases in investors' returns. All statements other than statements of historical fact in this document are "forward-looking statements". Forward-looking statements do not guarantee future performances. The financial projections included in this document do not constitute forecasts or budgets; they are purely illustrative examples based on a series of current expectations and assumptions which may not eventuate. The actual performance, results, financial condition and prospects of an investment interest may differ materially from those expressed or implied by the forward-looking statements in this document as the projected or targeted returns are inherently subject to significant economic, market and other uncertainties that may adversely affect performance. UBP also disclaims any obligation to update forward-looking statements, as a result of new information, future events or otherwise. The contents of this document should not be construed as any form of advice or recommendation to purchase or sell any security or funds. It does not replace a prospectus or any other legal documents, which can be obtained free of charge from the registered office of a fund or from UBP. The opinions herein do not take into account individual investors' circumstances, objectives, or needs. Each investor must make their own independent decision regarding any securities or financial instruments mentioned herein and should independently determine the merits or suitability of any investment. In addition, the tax treatment of any investment in the fund(s) mentioned herein depends on each individual investor's circumstances. Investors are invited to carefully read the risk warnings and the regulations set out in the prospectus or other legal documents and are advised to seek professional counsel from their financial, legal and tax advisors. The tax treatment of any investment in the Fund depends on the investor's individual circumstances and may be subject to change in the future. This document should not be deemed an offer nor a solicitation to buy, subscribe to, or sell any currency, funds, products, or financial instruments, to make any investment, or to participate in any particular trading strategy in any jurisdiction where such an offer or solicitation would not be authorised, or to any person to whom it would be unlawful to make such an offer or solicitation. Telephone calls to the telephone number stated in this presentation may be recorded. UBP will assume that, by calling this number, you consent to this recording.

Any subscriptions not based on the funds' latest prospectuses, KIIDs, annual or semi-annual reports or other relevant legal documents (the "Funds' Legal Documents") shall not be acceptable. The Funds' Legal Documents may be obtained free of charge from Union Bancaire Privée, UBP SA, 96-98 rue du Rhône, P.O. Box 1320, 1211 Geneva 1, Switzerland (UBP), from UBP Asset Management (Europe) S.A., 287-289 route d'Arlon, 1150 Luxembourg, Grand Duchy of Luxembourg, and from Union Bancaire Gestion Institutionnelle (France) SAS, 116 avenue des Champs-Élysées, 75008 Paris, France. The Swiss representative and paying agent of the foreign funds mentioned herein is UBP. The Funds' Legal Documents may be obtained free of charge from UBP, as indicated above.

**This content is being made available in the following countries:**

**Switzerland:** UBP is authorised and regulated in Switzerland by the Swiss Financial Market Supervisory Authority (FINMA). The head office is Union Bancaire Privée, UBP SA, 96-98 rue du Rhône, P.O. Box 1320, 1211 Geneva 1, Switzerland. [ubp@ubp.com](mailto:ubp@ubp.com) | [www.ubp.com](http://www.ubp.com)

**United Kingdom:** UBP is authorised in the United Kingdom by the Prudential Regulation Authority (PRA) and is subject to regulation by the Financial Conduct Authority (FCA) and limited regulation by the PRA.

**France:** Sales and distribution are carried out by Union Bancaire Gestion Institutionnelle (France) SAS, a management company licensed with the French Autorité des Marchés Financiers, - licence n° AMF GP98041 ; 116, av. des Champs Elysées | 75008 Paris, France T +33 1 75 77 80 80 Fax +33 1 44 50 16 19 [www.ubpamfrance.com](http://www.ubpamfrance.com).

**Hong Kong:** UBP Asset Management Asia Limited (CE No.: AOB278) is licensed with the Securities and Futures Commission to carry on Type 1 – Dealing in Securities, Type 4 – Advising on Securities and Type 9 – Asset Management regulated activities. The document is intended only for Institutional or Corporate Professional Investor and not for public distribution. The contents of this document have not been reviewed by the Securities and Futures Commission in Hong Kong. Investment involves risks. Past performance is not indicative of future performance. Investors should refer to the fund prospectus for further details, including the product features and risk factors. The document is intended only for **Institutional Professional Investor** and not for public distribution. The contents of this document and any attachments/links contained in this document are for general information only and are not advice. The information does not take into account your specific investment objectives, financial situation and investment needs and is not designed as a substitute for professional advice. You should seek independent professional advice regarding the suitability of an investment product, taking into account your specific investment objectives, financial situation and investment needs before making an investment. The contents of this document and any attachments/links contained in this document have been prepared in good faith. UBP Asset Management Asia Limited (UBP AM Asia) and all of its affiliates accept no liability for any errors or omissions. Please note that the information may also have become outdated since its publication. UBP AM Asia makes no representation that such information is accurate, reliable or complete. In particular, any information sourced from third parties is not necessarily endorsed by **UBP AM Asia**, and **UBP AM Asia** has not checked the accuracy or completeness of such third party information.

**Singapore:** This document is intended only for accredited investors and institutional investors as defined under the Securities and Futures Act (Cap. 289 of Singapore) ("SFA"). Persons other than accredited investors or institutional investors (as defined in the SFA) are not the intended recipients of this document and must not act upon or rely upon any of the information in this document. The financial products or services to which this material relates will only be made available to clients who are accredited investors or institutional investors under the SFA. This document has not been registered as a prospectus with the MAS. Accordingly, this document and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of this product may not be circulated or distributed, nor may the product be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to institutional investors under Section 274 or 304 of the Securities and Futures Act (Cap. 289) of Singapore ("SFA"), (ii) to relevant persons pursuant to Section 275(1) or 305(1), or any person pursuant to Section 275(1A) or 305(2) of the SFA, and in accordance with the conditions specified in Section 275 or 305 of the SFA, or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. This advertisement has not been reviewed by the Monetary Authority of Singapore.

**MSCI :** Although Union Bancaire Privée, UBP SA information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness of any data herein. None of the ESG Parties makes any express or implied warranties of any kind, and the ESG Parties hereby expressly disclaim all warranties of merchantability and fitness for a particular purpose, with respect to any data herein. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein. Further, without limiting any of the foregoing, in no event shall any of the ESG Parties have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.